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Abstract
Background: Complex chronic diseases are usually not caused by changes in a single causal gene but by an
unbalanced regulating network resulting from the dysfunctions of multiple genes or their products. Therefore,
network based systems approach can be helpful for the identification of candidate genes related to complex
diseases and their relationships. Axial spondyloarthropathy (SpA) is a group of chronic inflammatory joint diseases
that mainly affect the spine and the sacroiliac joints. The pathogenesis of SpA remains largely unknown.
Results: In this paper, we conducted a network study of the pathogenesis of SpA. We integrated data related to
SpA, from the OMIM database, proteomics and microarray experiments of SpA, to prioritize SpA candidate disease
genes in the context of human protein interactome. Based on the top ranked SpA related genes, we constructed a
SpA specific PPI network, identified potential pathways associated with SpA, and finally sketched an overview of
biological processes involved in the development of SpA.
Conclusions: The protein-protein interaction (PPI) network and pathways reflect the link between the two
pathological processes of SpA, i.e., immune mediated inflammation, as well as imbalanced bone modelling caused
new boneformation and bone loss. We found that some known disease causative genes, such as TNFand ILs, play
pivotal roles in this interaction.
Background
Axial spondyloarthropathy (SpA) is a family of chronic
inflammatory joint diseases of the spine and the sacroi-
liac joints. One of the major prototypes of SpA is anky-
losing spondylitis (AS). The two central features of SpA
are inflammation and new bone formation, especially in
the spine [1]. The inflammation first occurs around the
sites where ligaments attach to the bone. As the inflam-
mation heals, there is new bone formation in the liga-
ment, causing the thickening or hardening of the
underlying bone, and eventually the fusion of the verteb-
ral bodies and even the spinal stiffness. It is known that
SpA is associated with multiple genes, such as HLA-
B27, TNF and IL23R [2]. However, the pathogenesis of
SpA remains largely unknown. The complexity of the
disorder indicates a multifactorial etiology involving
multiple biological processes or pathways.
The pathogenesis of complex chronic diseases such as
SpA is believed to happen due to the malfunction of
multiple genes and gene products. It has been fairly well
confirmed that the propensity of many diseases can be
reflected by altered gene and protein expression levels
in particular cell types [3,4]. High throughput experi-
ments at transcriptomic and proteomic levels have been
applied to screen potentially disease associated factors of
SpA. Some genes involved in the innate immune system,
such as SPARC, SLPI and NLRP2, and proteins known
to be tumor necrosis factor (TNFa)inducible were iden-
tified to be up-expressed in SpA [4-7]. On the other
hand, disease associated genes tend to share common
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functional features, be co-expressed in specific tissues,
and their protein products have a tendency to interact
with each other [8]. Several computational methods
have been developed accordingly to predict disease asso-
ciated genes based on PPI [9-12], or the integration of
gene expression data with PPI [13-15]. Furthermore,
research has been conducted trying to identify patho-
genic processes by the integrated computational analysis
of heterogeneous data sources, including genetics, tran-
scriptomics, proteomics and interactome data. Many
specific disease-associated networks have been con-
structed, including those related to diabetes mellitus,
cancers, asthma, Alzheimer’s disease, and cardiovascular
diseases [16-27]. In addition, some cellular network or
signaling pathway databases have systematically col-
lected pathways associated with specific diseases
reported in the literature [28,29]. The disease-associated
networks have the promise of allowing for the better
understanding of disease pathogenesis, as well as for the
identification of potential target sets for therapeutic
intervention in the corresponding diseases.
In this work, we integrated SpA-active genes from dif-
ferent resources (known disease genes in the OMIM
database [30], proteomic and microarray experiments)
and proposed an approach to prioritize candidate genes
in the context of human interactome. We then took out
the genes most likely associated with SpA to construct a
PPI network of SpA and identified potential pathways
involved in SpA. Finally, we drew an overview picture of
biological processes involved in the development of SpA.
Results and discussion
Scoring and ranking genes in the PPI network
Our method to construct disease associated network is
based on the observation that proteins coded by genes
associated with the same disease tend to be closely
located to each other in the protein interaction network
[8,31,32]. Starting with a group of SpA-active genes as
seeds, we applied a Katz’ centrality based index [33] to
prioritize candidate genes in the PPI network [15].
Given a weighted human interactome represented as a
matrix W corresponding to the interaction strength
between genes, and a set D of k known disease-active
genes as seeds, we define vector x = (x1, x2,..., xn)
T as
initially known activity of genes in the disease, with xi =
1 if gene i is in the set D, xi = 0 otherwise. It should be
noted that our SpA-active gene set is a combination of
proteomics and microarray data, each of which actually
has different confidence levels for the study of disease
pathogenesis. A good way is to set different weights for
them. But determining the value of each weight makes
the solution much more difficult. For simplicity, we just
give them the same weight in this study.
Let s = (s1, s2,..., xn)
T be our score vector over the set
of genes (where si indicates how strong i is as a disease-
gene candidate),





where t indicates iteration time, and j is a parameter
that sets the relative contributions of the activity x and
links in protein interaction networks W to the score. If
j is small, the known activity is more important; if j is
large, the coupling to the protein neighbours is more
important. The parameter j needs to be calibrated with
real data. The score could be obtained by performing
iterations until the algorithm converges, and then all
genes in the PPI network could be ranked according to
their s-scores.
Equation (1) can be represented as matrix form as fol-
lows:
s = x + φWs (2)
which can be solved by matrix algebra:
s = [I− φW]−1x (3)
where [I-jW]-1 represents the inverse of the matrix I-
jW. We solved equation (3) by Jacobi iteration
algorithm.
To get a set of SpA-active genes as seeds, we inte-
grated the results of the proteomics and microarray
experiments for SpA and obtained 161 genes potentially
active in this disease (See Materials and Methods). Our
protein interaction network was constructed from the
STRING database [34]. A total of 147 of the 161 genes
were found present in the STRING PPI network, and
these genes were used as seeds to construct the disease
gene activity vector x in equation (3).
We searched the Online Mendelian Inheritance in
Man (OMIM) database [30] with a keyword “Spondy-
loarthropathy” and found 7 causal genes with Entrez
gene ID. These 7 genes were used to determine the
parameter j. For each of the genes, we determined a
candidate gene set of size N(N is about 100), including
this disease gene, which locate at, or near the cytogentic
loci of the SpA-causative gene. For a known SpA-causa-
tive gene in a candidate gene set of size N, if its s-rank
calculated by our algorithm is r, then r-ratio, defined as
r/N, could reflect how strong this gene is predicted as a
disease gene. We determined parameter j as the one
minimized the average r-ratios of the known SpA-causa-
tive genes.
For all the genes in the PPI network, we calculated the
s-score vector by equation (3). Then we ranked the
genes in each candidate disease gene set according to
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their s-cores and got their r-ratios. We repeated this
computation by applying different values of j in the
area (0, 1/100) and checked the average r-ratios of all
the 7 known OMIM disease genes. In this way, the best
value of j was determined as 10-4, which minimized the
average r-ratios of known OMIM disease genes for SpA.
For the optimum j = 10-4, we found an average r-ratio
of 0.186, suggesting that the known SpA causative genes
were averagely ranked top 18.6% of the candidate genes.
It was known that the performance of our method
could be enhanced when partial information about
known disease genes was included [15]. Having the opti-
mum value of j determined, we added the 7 known
SpA-causative genes into the seeds. Then all the genes
in the human PPI network were scored according to
equation (3).
PPI network of SpA
The s-score of a gene indicates its possibility associated
with the disease. Setting 10% as a cut-off, we took out
the genes whose s-scores were top 10% of all genes in
the PPI network. We identified a total of 380 genes.
Then we limited interactions in the STRING database
to weights of at least 0.5, which corresponds to a med-
ium-confidence human genome PPI network [34], and
constructed a subnetwork spanned by these 380 genes.
Finally, we obtained a PPI network associated with SpA,
which included 367 nodes and 8887 edges.
For 8887 interactions with strength at least 0.5
among only 367 gene-coded proteins, the PPI network
of SpA is densely connected. To understand its topol-
ogy, we conducted a k-core decomposition on the
network. A so-called k-core decomposition is a way to
visualize both of the connectivity of neighbourhoods of
nodes and their centrality [35]. In short, k-core decom-
positions are obtained by iteratively deleting low-
degree nodes to achieve a sequence of k-cores (maxi-
mal subgraphs with minimal degree k, see the Methods
section). By and large, following the k-core decomposi-
tion is similar to zooming into the more central and
more interconnected parts of the network. For the PPI
network we studied, the innermost core is the 42-core,
which includes 143 nodes. In Figure 1, we illustrate
the node distribution in the hierarchical k-core layers
of the PPI network and the number of seed genes in
the core layers. This figure suggests that the network
topology exhibits a core-periphery dichotomy [36,37] -
about half of the nodes in this network interact fre-
quently and are thus interconnected densely to form
an inner 36-core, while others communicate with
fewer nodes and scatter in different outer core layers
to form the periphery of the network. Figure 1 also
shows that most seed genes locate at the periphery
part whereas the inner core includes most of the non-
seed genes. Specifically, a total of 141 seed genes
appear in this network, in which only 16 are located in
the inner core. All nodes in the core layers 1~10 and
about half of the nodes in the core layers 11~35 are
seed nodes. Therefore, as shown in Figure 2, we parti-
tion the network into three parts accordingly - the
inner core is the 36-core, and the medium and outer
layers correspond to core layers 11~35 and 1~10,
respectively. It can be seen that seed genes in the
outer and medium layers tend to interact with genes
Figure 1 Distribution of k-core layers and seed nodes in the SpA PPI network.
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in the inner core, indicating that the inner core could
be the modulating centre of the network.
Furthermore, we searched the DrugBank database [38]
for drugs treating SpA and their protein targets. In fact,
currently there is no cure for SpA. Three classes of
drugs are used clinically for disease management, that
is, to reduce inflammation, relieve pain and stiffness,
suppress disease activity and slow disease progression
[39]. They are non-steroidal anti-inflammatory drug
(NSAID), TNF blocker and disease-modifying antirheu-
matic drug, while the third class shows disappointing
effects in practice [39]. We mapped the protein targets
of these drugs onto the SpA PPI network and found 7
targets in this network, i.e., PTGS2, MMP2, MAPK3,
HRAS, EGF, NFKB1 and TNF, in which PTGS2
(Cyclooxygenase 2)and TNF (Tumor necrosis factor) are
main therapeutic targets of NSAID and TNF blocker,
respectively, TNF and NFKB1 are targets for one of the
disease-modifying antirheumatic drugs Thalidomide.
TNF is also known disease gene of SpA. PTGS1
(Cyclooxygenase 1), the other therapeutic target of
NSAID, does not appear in this network because we
only took top 10% ranked genes in the global PPI net-
work. As shown in Figure 2, six of the seven targets are
located in the inner core of the SpA PPI network, and
only one situates at the outer layer, suggesting that the
drugs may interfere with the disease by acting on pro-
teins in the core.
To explore the implications of this PPI network to
SpA, we conducted gene ontology (GO) analysis. We
used the p-value to quantitatively measure whether this
PPI network is statistically significantly enriched with
genes of a specific Gene ontology (GO) term. In Table 1
we listed the most significantly enriched GO terms pre-
sented in the network, with p-values smaller than 0.001.
It can be seen that proteins in this network are signifi-
cantly involved in biological processes of immune sys-
tem, such as the regulation of granulocyte macrophage,
natural killer cell proliferation, as well as the activation
of leukocytes, lymphocytes and T cells, in consistent
with the immune-mediated feature of SpA.
The immune system process protects human beings
against diseases with increasing specificity. The innate
immune system provides an immediate, but non-specific
response to invading pathogens; and the adaptive
immune system, which is activated by the innate
response in case those pathogens successfully evaded
the response, adapts its response to improve its recogni-
tion of the pathogen. The innate immune response is
important in the initiation of, and interplay with, the
adaptive immune response. To investigate the associa-
tion between the innate immune response and SpA, we
constructed a subnetwork of the SpA PPI network
involved in the innate immune response, by mapping
proteins of the SpA network onto the PPI network of
human innate immune response constructed from the
InnateDB database [40] (see Figure 3). This subnetwork
includes about half of the nodes of the SpA network,
suggesting that the dysfunction of the innate immune
system could be associated with the development of
SpA. As can be seen in Figure 3, the innate immune
subnetwork is significantly enriched with core nodes
and non-seed nodes of the SpA PPI network (p-values
are less than 0.001). This observation indicates that a
very large fraction of proteins identified by our algo-
rithm (non-seed nodes) are involved in the innate
Figure 2 Core-periphery topology of the SpA PPI network. Blue, green and red nodes represent the inner core, the medium and outer core
layer, respectively. Triangles are seed genes, and diamonds are targets of drugs for SpA.
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immune response, suggesting that in the human genome
PPI network, the known SpA active proteins (seed nodes
in our study) are close to a common group of innate
immune proteins. Thus our approach reveals the impor-
tant role of innate immune system in the initiation and
development of SpA.
SpA injures the spine and the sacroiliac joints. It has
been known that any kind of damage to the bone is
mediated by osteoclasts, which are of hemopoietic cell
origin [41]. To explore the tissue specificity of the SpA
PPI network, considering that the interaction of two
proteins cannot occur in a tissue if one of the proteins
is not expressed in this tissue [42], we mapped proteins
in the SpA PPI network onto the tissue specific protein
expression dataset downloaded from the Human Protein
Atlas portal [43]. A total of 275 out of the 367 proteins
were identified in hemopoietic cells of bone marrow. As
shown in Figure 4, the intensity and quantity of 63%
proteins in this network could be detected in hemopoie-
tic cells of bone marrow with abundance levels varying
from weak to strong, suggesting a correlation of this
network to bone pathogenesis.
Pathways associated with SpA
To identify SpA-relevant biological processes, we
mapped the 380 SpA associated genes onto the KEGG
and Biocarta pathways, respectively. We used p-value to
measure if a pathway is more likely affected by SpA
associated genes (see Method part). Given significance
level a = 0.05, we found that a total of 40 KEGG path-
ways are significantly enriched with genes in this group
(see Additional file 1, Table S1). Similar pathways in the
Table 1 Selection of the most significantly enriched GO terms in the SpA PPI network
GO ID GO term Total genes Mapped genes
0032725 positive regulation of granulocyte macrophage colony-stimulating factor production 5 5
0032819 positive regulation of natural killer cell proliferation 7 6
0002376 immune system process 2239 144
0006950 response to stress 3586 151
0051716 cellular response to stimulus 6383 179
0010941 regulation of cell death 1549 91
0042127 regulation of cell proliferation 1402 81
0002694 regulation of leukocyte activation 404 58
0051249 regulation of lymphocyte activation 351 56
0050863 regulation of T cell activation 287 49
Figure 3 A subnetwork of the SpA PPI network involved in innate immune response. Blue, green and red nodes represent the inner core,
the medium and outer core layer of the SpA PPI network in Fig.2, respectively. Triangles are seed genes in Figure 2.
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Biocarta database are also enriched with SpA associated
genes. In Additional file 1, Table S2 we just listed four
SpA gene enriched pathways included in the Biocarta
database but not in the KEGG database.
A central feature of SpA is inflammation, one of the
first responses of the immune system to infection or
irritation. As listed in Additional file 1, Table S1, SpA is
related to a large fraction of pathways in immune sys-
tem. Some other pathways, although not classified into
immune system in the KEGG database, have been
known to be highly associated with the function of
immune response, such as apoptosis [44], MAPK signal-
ing pathway [45], and cell adhesion molecule interac-
tions [46]. Specifically, Additional file 1, Table S1
includes several pathways related to pathogen recogni-
tion and inflammatory signalling in innate immune
defences, in which the most important one is the Toll-
like receptor (TLR) signalling pathway. The innate
immune system relies on pattern recognition receptors
(PRRs) to detect distinct pathogen-associated molecular
patterns (PAMPs). Upon PAMP recognition, PRRs trig-
ger a number of different signal transduction pathways.
The pathways induced by PRRs ultimately result in the
expression of a variety of proinflammatory molecules,
such as cytokines, chemokines, cell-adhesion molecules,
and immunoreceptors, which together orchestrate the
early host response to infection, mediate the inflamma-
tory response, and also bridge the adaptive immune
response [46] together. The family of TLRs is the major
class of PRRs [46]. The association of TLR2 and TLR4
with SpA has been reported [47]. It was noticed that
three major signaling pathways were responsible for
mediating TLR-induced responses including NF-kB,
mitogen-activated protein kinases (MAPKs), and IFN
regulatory factors (IRFs) [46], while we found that the
two pathways, MAPKs and NF-kB, which play central
roles in induction of a proinflammatory response, are
involved in SpA. The tumor necrosis factor (TNFa) is
an important upstream protein of the NF-kB pathway,
which binds to its receptor to recruit TNF receptor
death domain (TRADD) and thus activates NF-kB. TNF
inhibitors have been proven highly effective for the
treatment ofSpA [1]. In addition, we also found that
SpA is associated with some proinflammatory molecule
involved pathways, such as the chemokine signaling
pathway, natural killer-cell mediated cytotoxicity, Fc
epsilon RI signaling pathway, and cell-adhesion mole-
cules interaction. These pathways indicate the process of
Figure 4 Distribution of abundance levels of proteins of the SpA PPI network in hemopoietic cells of bone marrow.
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innate immune response in the progress of SpA. On the
other hand, it is known that B and T lymphocytes are
responsible for the adaptive immune response [48]. Sup-
plementary Table S1 shows the association of B and T
cell receptor signalling pathways with SpA, implying
their function in the adaptive immune response in SpA.
In fact, it has been known that both the innate and
adaptive immune responses are involved and interde-
pendent with each other in SpA [49].
Another prominent feature of SpA is new bone forma-
tion; meanwhile bone loss is also a common finding in
SpA [50]. As can be seen in Additional file 1, Table S1
and S2, SpA is associated with osteoclast differentiatio-
nand bone remodelling pathways, biological processes
that maintain bone density and structure through a bal-
ance of bone resorption by osteoclasts and bone deposi-
tion by osteoblasts. Both ossification and osteoporosis
symptoms of SpA are consequences of an imbalance in
the regulation of these two sub-processes of bone remo-
delling. It is known that the WNT pathway regulates
the balance between osteoclast and osteoblast function
[51], verifying our result that SpA is associated with the
WNT pathway (see Additional file 1, Table S1). In Addi-
tional file 1, Figure S1 we show SpA associated genes
involved in the osteoclast differentiation pathway. Only
one SpA causative gene from the OMIM database and
three SpA active genes from the proteomics and micro-
array experiments appeared in this pathway, whereas a
great fraction of genes involved in this network were
predicted by our algorithm.
Finally, integrating the two features of SpA with genes
and pathways identified by our algorithm, we sketched
an overview of biological processes involved in the
development of SpA (Figure 5). Some SpA pathogenic
factors, which remain unclear yet [52], on the one hand,
trigger pathways of innate and adaptive immune
responses to produce proinflammatory molecules, lead-
ing to inflammatory response. On the other hand, they
also trigger progenitor cells, leading to unbalanced bone
remodelling. Different pathways regulate these two
aspects of pathological processes of SpA and interact
with each other, in which some cytokines such as TNF
and ILs, also known as SpA causative genes, play pivotal
roles.
Conclusions
We have extracted data related to SpA - known SpA
causative genes from the OMIM database, proteomic
Figure 5 Pathway of SpA. Pink: Omim genes; Yellow: genes differentially expressed in the gene expression or proteomics experiments; Green:
genes predicted by our algorithm.
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experiments from literature, and microarray experiments
from the GEO database. Using these genes as seeds, we
developed a Katz’-centrality based index, s-score, to rank
genes in the human PPI network. Then we considered
380 top-ranked genes as associated with SpA with high
possibility. Based on these genes, we constructed a PPI
network and identified potential pathways associated
with SpA. The PPI network exhibits a core-periphery
topology, in which most seed genes are located at the
periphery part, while the inner core aggregates the non-
seed genes enriched with innate immune genes and
drug targets for SpA, suggesting that the core could be
the modulating center of the network. The pathways we
have discovered in this way represent the common
knowledge of SpA, i.e., that it is an immune-mediated
inflammation. Our data also reflect that an imbalanced
bone modeling caused new bone formation and bone
loss. We also illustrated the interplay between inflamma-
tion and bone injure. This network approach represents
an alternative method for analyzing the complex effects
of candidate genes related to complex diseases.
Materials and methods
Collection of SpA-associated genes
We collected genes associated with SpA from three
resources as follows:
(1) The Online Mendelian Inheritance in Man
(OMIM) database [30]: The OMIM database contains
information on all known diseases and associated genes.
We searched the database with a keyword “Spondyloar-
thropathy” and found 8 causal genes: HLA-B, TNFA,
IL23R, CYP2D6, TNFSF13, TNFSF13B, B2M and
COL2A1, in which gene CYP2D6 does not have an
Entrez gene ID. The other seven genes are used as SpA-
causative genes in this study.
(2) Proteomic experiment results: quantitative proteo-
mics approaches were applied to investigate changes in
protein expression in AS (the most common prototype
of SpA) monocytes in comparison with healthy controls
[53]. We used the 42 genes (Entrez ID) whose encoded
proteins were differentially expressed [53] as potentially
active genes in SpA.
(3) The NCBI Gene Expression Omnibus (GEO) data-
base: we searched the GEO database and found 2 micro-
array experiments related to SpA: GSE1402 (Affymetrix
U95Av2) and GSE18781 (AffymetrixHG_U133_Plus2).
The GSE1402 experiment included a comparison of per-
ipheral blood mononuclear cells (PBMC) from juvenile
SpA with that of normal individuals, and the GSE18781
experiment was an investigation of peripheral blood
cells from 18 subjects with SpA and 25 normal indivi-
duals. Samples in the GSE18781 experiment were pro-
cessed as two separate sets at different times: 11 SpA +
12 control subjects in Set 1 and 7 SpA + 13 control
subjects in Set 2. We treated the results of these two
experiments as three separate datasets.
To integrate gene expression data from the two differ-
ent platforms, we mapped the probe sets of the plat-
forms to Entrez gene ID. This process yielded a set of
9448 genes common to the two platforms. For each
gene in a dataset, we calculated the average expression
level for probe sets associated with this gene, and fil-
tered out genes whose mean expression ratios (SpA over
control) in the two samples are greater than 0.67 (1/1.5)
and less than 1.5. In the next step, we converted the
expression value to its rank in the common genes [54].
Thereafter, a nonparametric two sample test, the Wil-
coxon rank-sum test, was used to test if a gene is differ-
entially expressed in the SpA and control samples and
the p-value of the Wilcoxon rank-sum test was
obtained. For such a large number of genes being simul-
taneously tested, the FDR [55] corrected p-values were
used for screening differentially expressed genes. Given
FDR level of 0.10, we found genes that are differentially
expresses in the two samples for each of the three data-
sets. We then combined differentially expressed genes in
the three datasets and identified 119 distinct genes
potentially active in SpA.
Finally, the combination of disease causative genes
from OMIM database, differentially expressed genes
from the proteomics and microarray experiments
yielded a total of 168 potentially SpA-active genes,
which were used in a subsequent analysis.
It is noted that the SpA associated genes collected
from the three resources have no overlap, which is likely
due to the different levels of data origins. OMIM genes
were collected from literatures focused on single gene
or protein studies, while microarray and proteomic data
were generated from genome-scale experiments at dif-
ferent levels. It is known that the activity of gene and
protein is highly dynamic and can change rapidly in
response to changes in internal and external environ-
ments. However, most current genome-scale experi-
ments could not capture the entire dynamics but only
take snapshots at single time points in specific experi-
mental settings. This is why in most cases these data
have little overlap. In order to get a better view of the
disease pathology, we need to integrate different data
resources.
Candidate disease genes
We downloaded human gene location data from the ftp
of NCBI MapViewer [56], which include the chromoso-
mal locations and chromosomal base pair ranges of
human genes. For each of the 7 known SpA-causative
genes, we determined a set of N candidate genes,
including this disease gene, which locate at, or near the
cytogentic loci of the disease gene. Here, the number of
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candidate genes is about 100. If the chromosomal region
where the disease gene located has more than 100
genes, we took 100 genes near the disease gene as can-
didates; otherwise, we took all genes in this region.
Protein-protein interaction data
Weighted protein-protein interactions (PPI) of human
beings were downloaded from version 8.3 of STRING
[34]. STRING includes both physical and functional
interactions integrated from numerous sources, includ-
ing experimental repositories, computational prediction
methods and public text collections; uses a scoring sys-
tem to weigh the evidence of each interaction; and
includes the interactions between 14532 proteins (Entrez
gene ID) of human genome. We normalized the interac-
tion scores in STRING to the area [0, 1] and repre-
sented the weighted PPI network as a matrix W.
Innate immunity-relevant human proteins and their
interactions were downloaded from the InnateDB data-
base [40] on April 25, 2011. Till the day we downloaded
the data, this database includes 2310 human genes and
4819 interactions manually collected by literature
review.
Tissue specific protein expression data
Protein expression data in human normal tissue were
downloaded from the web of the Human Protein Atlas
[43]. Human Protein Atlas portal is a publicly available
database including the spatial distribution and the rela-
tive abundance of proteins in 46 different normal
human tissues and 20 different cancer types, as well as
47 different human cell lines. The protein abundance
scales were combined into four levels: negative, weak,
moderate and strong. We downloaded the file named
normal_tissue.csv on September 16, 2011 and then
extracted proteins expressed in hematopoietic cells of
bone marrow and their abundance scales. This dataset
includes 10798 gene-coded proteins (Entrez ID) in total.
Pathway data
We downloaded pathway data from the FTP service of
KEGG [57] (Kyoto Encyclopedia of Genesand Genomes)
on June 21, 2011. The KEGG PATHWAY section is a
collection of manually drawn pathway maps represent-
ing the information on the molecular interaction and
reaction networks. The hsa_pathway.list file in this sec-
tion includes a list of known proteins encoded by H.
sapiens’s genome and the corresponding pathways in
which these proteins are involved.
k-core and k-core layer
The k-core of a graph is the maximal subgraph such
that all of its nodes has at least k links within the sub-
graph [35,58]. The k-core layer lk is defined as the set of
nodes that belong to k-core but not to k+1-core, i.e., k-
core is the union of k+1-core and k-core layer. A k-core
subgraph of a graph can be generated by recursively
deleting the vertices from the graph whose present
degree is less than k. This process can be iterated to
gradually zoom into the more connected parts of the
network. The higher-level core corresponds to more
densely connected part of the network. See Figure 6 for
an explanation.
P-value
If we randomly draw n samples from a finite set, the
probability of getting i samples with the desired feature
by chance obeys the hypergeometric distribution with













Where N is the size of the set, K is the number of
items with the desired feature in the set. Then the prob-
ability, defined as the P-value, of getting at least k sam-
ples with the desired feature by chance can be obtained
as the following, using the hypergeometric cumulative
distribution function (CDF),
p = 1 −
∑k−1
i=0














Figure 6 Illustration of k-core and k-core layer. The 1-core layer
are the red nodes, the 2-core layer are green. The 1-core is the
whole graph, the 2-core is subgraph consisting of green and blue
nodes and the 3-core is the subgraph consisting of blue nodes.
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Given a significance level a, a p-value smaller than a
demonstrates a low probability that the items with the
desired feature are chosen by chance. Hence this p-
value can be used to measure whether the n samples
drawn from the set is more enriched with items of the
desired feature than would be expected by chance [59].
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